Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Personalized cancer vaccines combined with check-point inhibitors hold promise for future therapies for cancer. It remains, however, unclear whether optimal epitopes for vaccination should be mutated or whether germ-line epitopes may also have some merits. In addition, it has remained difficult to induce strong cytotoxic T cell responses in vivo in the absence of viral vectors. Here we develop a personalized cancer vaccine platform based on virus-like particles (VLPs) loaded with toll-like receptor ligands and generate three sets of multi-target vaccines: One set based on germ-line epitopes (GL-MTV) identified by immune-peptidomics, one set based on mutated epitopes (Mutated- MTV) and one set that combines the two (Mix-MTV). Vaccine efficacy was tested in mice transplanted with B16F10 melanoma tumors to have a realistic, well vascularized and in situ established cancer model. Our results demonstrate that both germ-line and mutated neo-epitopes induced partial protection but best protection was achieved with a cocktail containing both types of peptides. Thus, both germ-line and neo-epitopes are valuable targets and VLP-based vaccines displaying both types of epitopes may confer optimal protection.


Conference paper

Publication Date





34S - 34S


VLPs, vaccine, personalized, click chemistry, immunopeptidomics, exome-sequencing, germ-line epitopes, mutated epitopes, multi-target vaccine